September 11, 2026

This information is correct as of the date given above. For further details and any updates on the information below, please refer to the Company's Press Releases and financial documentation.

Questions & Answers on Ocumension Therapeutics, Nicox's commercial partner for NCX 470 in China

The Chinese NDA for NCX 470 (referred to 0T-301 by Ocumension) was submitted in August 2026 and is expected to have a review time of 12 to 18 months. NCX 470 would be commercialised in China by Ocumension Therapeutics, if the NDA is approved. Below we answer common questions about Ocumension and their capabilities for the commercialisation of NCX 470. Commercial launch of NCX 470 in China is conditional upon its approval by China's National Medical Products Administration (NMPA).

1. **Who is Ocumension?**

Ocumension (full name Ocumension Therapeutics) is one of China's leading ophthalmic pharmaceutical companies focused on developing and commercialising ophthalmic therapies. Since its inception, the company has focused on building a business which spans research and development, and manufacturing to commercialisation in ophthalmology.

2. **Is Ocumension listed on a stock exchange?**

Yes. Ocumension is listed on the Hong Kong Stock Exchange.

3. **Does Ocumension have experience in ophthalmology?**

Yes. Ocumension is a specialist ophthalmology company focused exclusively on developing and commercialising ophthalmic products.

4. **What commercial capabilities does Ocumension have in China?**

Ocumension is a specialist ophthalmology company with all essential functions of the pharmaceutical industry in China. It has twenty-seven commercialised products, five drug candidates in Phase III clinical trials and one drug candidate at the registration stage, covering both front- and back-of-the-eye diseases. Ocumension also has experience in glaucoma with a number of intraocular pressure-lowering medications already on the market. Ocumension's

commercial network covers more than 22,000 hospitals across China, and a commercial team of more than 330 members.

5. **Does Ocumension have experience taking drugs through late-stage development and regulatory approval in China?**

Yes. Ocumension has received approvals for several drugs in China and currently has additional drug candidates in late-stage clinical development and registration.

6. **Does Ocumension have an established ophthalmology business in China?**

Yes. In its 2025 annual results, Ocumension reported 27 commercialised products and revenue of RMB 804.4 million, representing year-on-year growth of 92.7%.

7. **What is Ocumension's role in the development and commercialising NCX 470 in China?**

Ocumension holds exclusive rights to develop and commercialise NCX 470 in China, Korea and Southeast Asia under an agreement with Nicox signed in 2018. Ocumension has participated in the development of NCX 470, including contributing 50% of the costs of the Denali Phase 3 clinical trial, which included clinical sites in China, this enabled the China NDA to be submitted using the same clinical efficacy package as for the U.S. NDA.

Ocumension submitted the Chinese NDA in August 2026, with a review period expected to be 12-18 months. Subject to NMPA approval, Ocumension will be responsible for all activities related to the commercialisation of NCX 470 in China, including regulatory, manufacturing, marketing and sales.

8. **What is the relationship between Nicox and Ocumension?**

Nicox and Ocumension have been collaborating since 2018, when they entered into the first of several licensing agreements between the two companies. Ocumension also commercialises Nicox's product ZERVIATE©, 0.24% (cetirizine ophthalmic solution) in China.

9. **What is Nicox's role in the commercialisation of NCX 470 in China?**

Nicox will continue to provide its expertise relating to NCX 470 and nitric oxide to Ocumension throughout the collaboration. Beyond this support, Nicox's ongoing obligations in China are limited to maintaining intellectual property for NCX 470. Nicox's ongoing costs associated with NCX 470 in China are therefore not significant.

10. **What will Nicox receive from Ocumension for commercialisation of NCX 470?**

Ocumension will pay Nicox tiered royalties on sales of NCX 470 in China, starting at 6% and potentially reaching 12%, depending on sales levels. This same royalty structure will apply to any sales of NCX 470 in Korea or Southeast Asia.

Globally, Nicox could receive up to €136 million in future milestone payments, as well as royalties on global sales. Nicox has already received €39.5 million in global licensing payments for NCX 470.

11. What is the status of the NCX 470 NDA in China?

The NCX 470 NDA in China was submitted in August 2026. On September 11, Nicox and Ocumension announced that the NDA had been accepted for review by China's National Medical Products Administration (NMPA). This means that the dossier is considered complete. A decision is expected within 12 to 18 months of the submission.

12. Where can I find further information about Ocumension?

For further information, please visit Ocumension Therapeutic's website at www.ocumension.com.